PE20081842A1 - Composicion de liberacion sostenida y metodos para producirlas - Google Patents

Composicion de liberacion sostenida y metodos para producirlas

Info

Publication number
PE20081842A1
PE20081842A1 PE2008000035A PE2008000035A PE20081842A1 PE 20081842 A1 PE20081842 A1 PE 20081842A1 PE 2008000035 A PE2008000035 A PE 2008000035A PE 2008000035 A PE2008000035 A PE 2008000035A PE 20081842 A1 PE20081842 A1 PE 20081842A1
Authority
PE
Peru
Prior art keywords
sustained release
peptide
composition
pro
refers
Prior art date
Application number
PE2008000035A
Other languages
English (en)
Inventor
Tomomichi Futo
Kazuhiro Saito
Tetsuo Hoshino
Masuhisa Hori
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39015849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20081842A1 publication Critical patent/PE20081842A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION SOSTENIDA QUE COMPRENDE UN ALTO CONTENIDO DE UN PEPTIDO FISIOLOGICAMENTE ACTIVO DE FORMULA: 5-OXO-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z, EN DONDE Y ES DLeu, DAla, DTrp, DSer (tBu), D2Na1 O DHis (ImBz1) Y Z ES NH-C2H5 O Gly-NH2; DONDE DICHO PEPTIDO, SOLUBLE EN AGUA, ES DISPERSADO EN FORMA SUSTANCIALMENTE UNIFORME EN UNA MICROCAPSULA COMPUESTA POR UN POLIMERO DE ACIDO LACTICO QUE TIENE UN PESO MOLECULAR PROMEDIO DE 11,000 A 27,000 Y EL PEPTIDO ACTIVO ESTA CONTENIDO EN UNA CANTIDAD DE 15 A 35% P/P CON RESPECTO A LAS MICROCAPSULAS TOTALES. DICHA COMPOSICION PRESENTA UNA UN ALTO CONTENIDO DE LA SUSTANCIA ACTIVA Y LA SUPRESION DE LA LIBERACION INICIAL EXCESIVA DENTRO DE UN DIA DESPUES DE LA ADMINISTRACION Y UNA LIBERACION SOSTENIDA DE LA DROGA, ESTABLE DURANTE UN PERIODO DE TIEMPO PROLONGADO; SIENDO UTIL EN EL TRATAMIENTO DE CANCER DE MAMA, PROSTATA, ENDOMETRIOSIS, HIPERPLASIA PROSTATICA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE DICHA COMPOSICION
PE2008000035A 2006-12-18 2008-01-02 Composicion de liberacion sostenida y metodos para producirlas PE20081842A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87536406P 2006-12-18 2006-12-18
US91740107P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
PE20081842A1 true PE20081842A1 (es) 2009-01-19

Family

ID=39015849

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000035A PE20081842A1 (es) 2006-12-18 2008-01-02 Composicion de liberacion sostenida y metodos para producirlas

Country Status (27)

Country Link
US (3) US8921326B2 (es)
EP (1) EP2094246B1 (es)
JP (2) JP4564098B2 (es)
KR (1) KR101522035B1 (es)
CN (1) CN101563068B (es)
AR (1) AR064381A1 (es)
AU (1) AU2007335406B2 (es)
BR (1) BRPI0720582B1 (es)
CA (1) CA2671670C (es)
CL (1) CL2007003658A1 (es)
CO (1) CO6180498A2 (es)
CR (1) CR10867A (es)
DO (1) DOP2009000144A (es)
EA (1) EA016176B1 (es)
EC (1) ECSP099439A (es)
ES (1) ES2791698T3 (es)
GE (1) GEP20125597B (es)
IL (1) IL198845A (es)
MA (1) MA31006B1 (es)
MX (1) MX2009006653A (es)
MY (1) MY148370A (es)
NO (1) NO347209B1 (es)
NZ (1) NZ577281A (es)
PE (1) PE20081842A1 (es)
TN (1) TN2009000197A1 (es)
TW (1) TWI481424B (es)
WO (1) WO2008075762A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094246B1 (en) 2006-12-18 2020-04-01 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
WO2011078394A2 (en) * 2009-12-22 2011-06-30 Takeda Pharmaceutical Company Limited Sustained-release formulation
UY33465A (es) * 2010-06-25 2012-01-31 Takeda Pharmaceutical Formulacion de liberacion sostenida
US20150087624A1 (en) * 2012-04-24 2015-03-26 Osaka University Method for producing an aqueous dispersion of drug nanoparticles and use thereof
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
MX2020003681A (es) * 2017-09-26 2020-08-03 Nanomi B V Metodo para preparar microparticulas por tecnica de doble emulsion.
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
BR112022000413A2 (pt) * 2019-07-12 2022-03-03 G2Gbio Inc Formulação de longa duração contendo rivastigmina e método para preparar a mesma

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) * 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
EP0452111B1 (en) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
DE69316101T2 (de) * 1992-08-07 1998-10-22 Takeda Chemical Industries Ltd Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DE4342092B4 (de) 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
CA2143044C (en) * 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
JPH07273447A (ja) 1994-03-29 1995-10-20 Sumitomo Kinzoku Ceramics:Kk セラミック回路基板及びその製造方法
US5763513A (en) * 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
FR2736508B1 (fr) 1995-07-13 1997-09-19 Francais Prod Ind Cfpi Nouvelle forme solide de stockage et de commercialisation pour compositions phytosanitaires et moyens pour sa preparation
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
CA2219698C (en) * 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
IL136951A0 (en) * 1998-01-16 2001-06-14 Takeda Chemical Industries Ltd Sustained-release composition, method of its production and use thereof
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
AU2745199A (en) 1998-03-04 1999-09-20 Takeda Chemical Industries Ltd. Sustained-release preparation for aii antagonist, production and use thereof
US6114495A (en) * 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6270802B1 (en) * 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
AU1797800A (en) * 1998-12-15 2000-07-03 Takeda Chemical Industries Ltd. Process for producing polymer
WO2001005380A1 (fr) 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Compositions a liberation lente, techniques de production et methodes d'utilisation
AU6510400A (en) 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
WO2002012369A1 (fr) 2000-08-07 2002-02-14 Wako Pure Chemical Industries, Ltd. Polymere d'acide lactique et son procede de preparation
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2002043766A1 (fr) 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
AU2002221139A1 (en) 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
CA2471521C (en) * 2001-12-26 2010-11-02 Takeda Chemical Industries, Ltd. Novel microsphere and method for production thereof
CA2490351C (en) * 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US6803708B2 (en) * 2002-08-22 2004-10-12 Cdream Display Corporation Barrier metal layer for a carbon nanotube flat panel display
EP1660039B1 (en) 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
JP2007537137A (ja) * 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
EP3173072A1 (en) 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
WO2006053175A2 (en) 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
EP2094246B1 (en) 2006-12-18 2020-04-01 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same

Also Published As

Publication number Publication date
EA200970600A1 (ru) 2009-12-30
IL198845A (en) 2015-07-30
US9713595B2 (en) 2017-07-25
JP4564098B2 (ja) 2010-10-20
JP5258844B2 (ja) 2013-08-07
AR064381A1 (es) 2009-04-01
EA016176B1 (ru) 2012-02-28
CA2671670C (en) 2015-02-10
US8921326B2 (en) 2014-12-30
MX2009006653A (es) 2009-07-02
US20170165204A1 (en) 2017-06-15
AU2007335406B2 (en) 2012-09-13
BRPI0720582A2 (pt) 2014-02-04
NO20092662L (no) 2009-09-07
IL198845A0 (en) 2010-02-17
MA31006B1 (fr) 2009-12-01
CO6180498A2 (es) 2010-07-19
BRPI0720582B1 (pt) 2021-08-24
US20110135741A1 (en) 2011-06-09
US20150080322A1 (en) 2015-03-19
EP2094246B1 (en) 2020-04-01
TN2009000197A1 (en) 2010-10-18
MY148370A (en) 2013-04-15
NO347209B1 (no) 2023-07-03
KR20090094272A (ko) 2009-09-04
KR101522035B1 (ko) 2015-05-20
JP2010513225A (ja) 2010-04-30
ES2791698T3 (es) 2020-11-05
CA2671670A1 (en) 2008-06-26
TW200833376A (en) 2008-08-16
AU2007335406A1 (en) 2008-06-26
TWI481424B (zh) 2015-04-21
ECSP099439A (es) 2009-07-31
CN101563068B (zh) 2013-03-20
EP2094246A1 (en) 2009-09-02
CN101563068A (zh) 2009-10-21
NZ577281A (en) 2011-12-22
US9617303B2 (en) 2017-04-11
CR10867A (es) 2009-07-30
WO2008075762A1 (en) 2008-06-26
GEP20125597B (en) 2012-08-10
JP2010222371A (ja) 2010-10-07
CL2007003658A1 (es) 2008-05-09
DOP2009000144A (es) 2009-07-30

Similar Documents

Publication Publication Date Title
PE20081842A1 (es) Composicion de liberacion sostenida y metodos para producirlas
EA201170297A1 (ru) Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
MY167123A (en) Conveniently implantable sustained release drug compositions
WO2007098443A3 (en) Apparatuses and techniques for bioactive drug delivery in the prostate gland
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
MX2009004856A (es) Matriz polimerica insoluble en agua para suministro de farmaco.
IN2013MN02384A (es)
WO2012054500A3 (en) Compositions for drug administration
AR026986A1 (es) Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion
TR201905174T4 (tr) Lokal analjezi, lokal anestezi veya sinir blokajı sağlamak için bir ilaç iletim cihazı.
CN104159594A (zh) 用于皮肤病治疗的凯莫瑞c15肽的局部制剂
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
MX2011012043A (es) Sistema farmaceutico para suministro transmembrana.
MX2018006299A (es) Analogos de peptido de la hormona de estimulacion de alfa-melanocito.
ES2389627T3 (es) Formulación para bioimplantes
PE20030069A1 (es) Composicion de liberacion sostenida y proceso para producirla
WO2010009116A3 (en) Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
Teutonico et al. Leuprolide acetate: pharmaceutical use and delivery potentials
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
MX2009011900A (es) Curacion de herida diabetica.
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions

Legal Events

Date Code Title Description
FG Grant, registration